Synercid Advisory Committee Nod Driven by Need for VREF Antibiotics

The over 50% clinical efficacy of Rhone-Poulenc Rorer's Synercid (quinupristin/dalfopristin) in vancomycin-resistant Enterococcus faecium infections demonstrates enough benefit for approval because of the lack of marketed agents for the indication, FDA's Anti-Infective Drugs Advisory Committee concluded Feb. 19.